Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026

Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026

Ocular to host webcast scheduled for Tuesday, February 17, 2026, at 8:00 AM ET Detailed SOL-1 data to be presented at the 49th Macula Society Annual Meeting BEDFORD, Mass., Feb....

Ocular Therapeutix to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026

February 13, 2026 17:00 ET  | Source: Ocular Therapeutix, Inc. Ocular to host webcast scheduled for Tuesday, February 17, 2026, at 8:00 AM ET Detailed SOL-1 data to be presented at the 49th Macula Society Annual Meeting BEDFORD, Mass., Feb. 13, 2026 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company […] The post Ocular Therapeutix to Announce Topline Data for SOL-1 Phase 3 Superiority Tr…

Eye drug trial results: Ocular Therapeutix to outline wet AMD data Feb. 17

Topline SOL-1 Phase 3 data for wet age-related macular degeneration will be reviewed on a Feb. 17 webcast, ahead of detailed results at the Macula Society.